David Golod

Biography

David Golod brings a strong and broad background in drug development to Flex Pharma with 18 years of experience in the Pharmaceutical Industry. David started in Clinical Research at Solvay Pharmaceuticals, where he was the Senior Clinical Scientist of Cardiovascular Clinical Operations and Medical Affairs. David followed his time at Solvay becoming the Director of Clinical Research at Akros Pharma, Inc. where he worked on Phase I - Phase II programs across nine separate therapeutic areas. After his time at Akros, David led the clinical development programs for Pear Tree Pharmaceuticals focusing on Women’s Health and helped Javelin Pharmaceuticals file an NDA for Dyloject. Most recently, David headed the Program Operations Management Department within Clinical Development Execution at Vertex Pharmaceuticals in Boston, where he was responsible for planning, execution, and oversight of all clinical programs for Cystic Fibrosis, Oncology, and Pain. Most notably, the clinical programs that David oversaw at Vertex resulted in approvals for Kalydeco and Orkambi, successful completion and readout of the VX-661 CFTR Corrector Program, and initiation of the clinical programs for the Next Generation CFTR Correctors. David received his Ph.D. in Physiological and Pharmacological Sciences from Emory University in Atlanta. He received his M.B.A. from the University of the Sciences in Philadelphia and his B.S. in Biomedical Engineering from Purdue University. 

Research Interest

Cystic Fibrosis, Oncology, and Pain